NICE approves new prostate cancer treatment

In collaboration with the Press Association

The UK medical watchdog NICE has approved the use of chemotherapy drug docetaxel to treat men with advanced prostate cancer.

The new treatment has been shown to reduce pain and weight loss and to increase survival by up to 25 per cent. It was originally developed for patients with breast cancer.

It is particularly useful for patients no longer responding to hormone therapy.

The drug has now been approved for general availability on the NHS. Consultant oncologist professor Nick James described the decision as a "significant leap forward".

He warned the BBC that the treatment may not be available immediately from all primary care trusts, however.

Around 30,000 men in the UK are diagnosed with prostate cancer every year and around 10,000 die from it.